Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Lancet Oncol

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    February 2019
  1. ALSHAFA F, Palma D
    CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30953.
    PubMed     Text format    


  2. BALL D, Mai GT, Vinod S, Babington S, et al
    Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30896.
    PubMed     Text format     Abstract available


    November 2018
  3. SOLOMON BJ, Besse B, Bauer TM, Felip E, et al
    Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Lancet Oncol. 2018 Nov 6. pii: S1470-2045(18)30649.
    PubMed     Text format     Abstract available


    September 2018
  4. ROSELL R, Karachaliou N
    Avelumab in non-small-cell lung cancer.
    Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30683.
    PubMed     Text format    


  5. BARLESI F, Vansteenkiste J, Spigel D, Ishii H, et al
    Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
    Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30673.
    PubMed     Text format     Abstract available


  6. BLACKHALL F, Frese KK, Simpson K, Kilgour E, et al
    Will liquid biopsies improve outcomes for patients with small-cell lung cancer?
    Lancet Oncol. 2018;19:e470-e481.
    PubMed     Text format     Abstract available


    August 2018
  7. HIOM SC, Kumar HS, Swanton C, Baldwin DR, et al
    Lung cancer in the UK: addressing geographical inequality and late diagnosis.
    Lancet Oncol. 2018;19:1015-1017.
    PubMed     Text format    


    July 2018
  8. GLANVILLE AR, Wilson BE
    Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma.
    Lancet Oncol. 2018;19:e351-e358.
    PubMed     Text format     Abstract available


    June 2018
  9. GOURD E
    Lung cancer incidence higher in US women than men.
    Lancet Oncol. 2018 Jun 1. pii: S1470-2045(18)30422.
    PubMed     Text format    


    April 2018
  10. ROLFO C, Smits ELJ
    Combining top-ranked immunotherapeutics in lung cancer.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30186.
    PubMed     Text format    


  11. WRANGLE JM, Velcheti V, Patel MR, Garrett-Mayer E, et al
    ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30148.
    PubMed     Text format     Abstract available


    March 2018
  12. LIN JJ, Gainor JF
    ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
    Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30160.
    PubMed     Text format    


  13. GARASSINO MC, Cho BC, Kim JH, Mazieres J, et al
    Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30144.
    PubMed     Text format     Abstract available


  14. FIELD JK, Heuvelmans MA, Devaraj A, Heussel CP, et al
    Low-dose CT for lung cancer screening - Authors' reply.
    Lancet Oncol. 2018;19:e135-e136.
    PubMed     Text format    


  15. BACH PB, Brawley OW, Silvestri GA
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e133-e134.
    PubMed     Text format    


  16. RUANO-RAVINA A, Perez-Rios M, Casan-Clara P, Provencio-Pulla M, et al
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e131-e132.
    PubMed     Text format    


  17. WU YL, Zhong WZ
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2018;19:e127.
    PubMed     Text format    


  18. ROSELL R, Karachaliou N
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e126.
    PubMed     Text format    


  19. MA JA, Jiang S, Hu C, Xie Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e125.
    PubMed     Text format    


  20. WU F, Liu X, Ma JA, Gao Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e124.
    PubMed     Text format    


    February 2018
  21. ILEANA-DUMBRAVA E, Subbiah V
    Autoimmune hypophysitis.
    Lancet Oncol. 2018;19:e123.
    PubMed     Text format    


    January 2018
  22. CHENG H, Perez-Soler R
    Leptomeningeal metastases in non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e43-e55.
    PubMed     Text format     Abstract available


  23. WU YL, Mok TS
    Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.
    Lancet Oncol. 2018;19:e5.
    PubMed     Text format    


  24. ADDEO A
    Dacomitinib in NSCLC: a positive trial with little clinical impact.
    Lancet Oncol. 2018;19:e4.
    PubMed     Text format    


  25. NG TL, Camidge DR
    Lung cancer's real adjuvant EGFR targeted therapy questions.
    Lancet Oncol. 2018;19:15-17.
    PubMed     Text format    


  26. PIRKER R
    EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation.
    Lancet Oncol. 2018;19:10-12.
    PubMed     Text format    


  27. STIRRUPS R
    Osimertinib improves progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e10.
    PubMed     Text format    


  28. GOURD E
    Durvalumab boosts progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e11.
    PubMed     Text format    


  29. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
    Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Lancet Oncol. 2018;19:139-148.
    PubMed     Text format     Abstract available


  30. HERBST RS, Redman MW, Kim ES, Semrad TJ, et al
    Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Lancet Oncol. 2018;19:101-114.
    PubMed     Text format     Abstract available


    December 2017
  31. OUDKERK M, Devaraj A, Vliegenthart R, Henzler T, et al
    European position statement on lung cancer screening.
    Lancet Oncol. 2017;18:e754-e766.
    PubMed     Text format     Abstract available


  32. EMERY JD, Mitchell PL
    Lung cancer in Asian women and health system implications for Australia.
    Lancet Oncol. 2017;18:1570-1571.
    PubMed     Text format    


  33. BRAHMER JR, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Lancet Oncol. 2017;18:1600-1609.
    PubMed     Text format     Abstract available


  34. FEROLLA P, Brizzi MP, Meyer T, Mansoor W, et al
    Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2017;18:1652-1664.
    PubMed     Text format     Abstract available


    November 2017
  35. WEISS J
    Bevacizumab in adjuvant treatment of non-small-cell lung cancer.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30843.
    PubMed     Text format    


  36. WAKELEE HA, Dahlberg SE, Keller SM, Tester WJ, et al
    Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30691.
    PubMed     Text format     Abstract available


    October 2017
  37. SHAW AT, Felip E, Bauer TM, Besse B, et al
    Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Lancet Oncol. 2017 Oct 23. pii: S1470-2045(17)30680.
    PubMed     Text format     Abstract available


  38. DE KONING HJ
    Lung cancer screening and its continuous risk assessment.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30730.
    PubMed     Text format    


  39. TAMMEMAGI MC, Schmidt H, Martel S, McWilliams A, et al
    Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30597.
    PubMed     Text format     Abstract available


  40. FAIVRE-FINN C, Ryder WD, Blackhall F
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.
    Lancet Oncol. 2017;18:e556.
    PubMed     Text format    


  41. EZE C, Roengvoraphoj O, Dantes M, Manapov F, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e555.
    PubMed     Text format    


  42. MITIN T, Farrell M, Holland J, Cetnar J, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e554.
    PubMed     Text format    


  43. ZENG H, Yu J, Yuan S
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e553.
    PubMed     Text format    


  44. VAN ZANDWIJK N, Pavlakis N, Kao SC, Linton A, et al
    Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    Lancet Oncol. 2017;18:1386-1396.
    PubMed     Text format     Abstract available


  45. PAVEL ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, et al
    Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase
    Lancet Oncol. 2017;18:1411-1422.
    PubMed     Text format     Abstract available


    September 2017
  46. BRUECKL WM
    Treatment choice in EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30684.
    PubMed     Text format    


  47. WU YL, Cheng Y, Zhou X, Lee KH, et al
    Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30608.
    PubMed     Text format     Abstract available


  48. PLANCHARD D, Smit EF, Groen HJM, Mazieres J, et al
    Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
    Lancet Oncol. 2017 Sep 8. pii: S1470-2045(17)30679.
    PubMed     Text format     Abstract available


  49. PERROT M, Wu L, Wu M, Cho BCJ, et al
    Radiotherapy for the treatment of malignant pleural mesothelioma.
    Lancet Oncol. 2017;18:e532-e542.
    PubMed     Text format     Abstract available


  50. MAIO M, Scherpereel A, Calabro L, Aerts J, et al
    Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
    Lancet Oncol. 2017;18:1261-1273.
    PubMed     Text format     Abstract available


    July 2017
  51. AKAMATSU H, Takahashi T, Yamamoto N
    Prophylactic cranial irradiation in small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2017;18:e369.
    PubMed     Text format    


  52. FAN X, Liang F, Zhu J
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e368.
    PubMed     Text format    


  53. WEISS GJ, Lohinai Z
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e367.
    PubMed     Text format    


  54. MANAPOV F, Eze C
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e366.
    PubMed     Text format    


  55. RUSTHOVEN CG, Kavanagh BD
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e365.
    PubMed     Text format    


  56. DEL PAGGIO JC, Sullivan R, Schrag D, Hopman WM, et al
    Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Lancet Oncol. 2017;18:887-894.
    PubMed     Text format     Abstract available


    June 2017
  57. BROWER V
    Atezolizumab in advanced non-small-cell lung cancer.
    Lancet Oncol. 2017 Jun 22. pii: S1470-2045(17)30504.
    PubMed     Text format    


  58. FAIVRE-FINN C, Snee M, Ashcroft L, Appel W, et al
    Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30318.
    PubMed     Text format     Abstract available


  59. FIETKAU R
    Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?
    Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30439.
    PubMed     Text format    


  60. SHAW AT, Kim TM, Crino L, Gridelli C, et al
    Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30339.
    PubMed     Text format     Abstract available


    May 2017
  61. SHAVERDIAN N, Lisberg AE, Bornazyan K, Veruttipong D, et al
    Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
    Lancet Oncol. 2017 May 24. pii: S1470-2045(17)30380.
    PubMed     Text format     Abstract available


  62. DAS M
    Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30342.
    PubMed     Text format    


    March 2017
  63. GULLEY JL, Rajan A, Spigel DR, Iannotti N, et al
    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Lancet Oncol. 2017 Mar 31. pii: S1470-2045(17)30240.
    PubMed     Text format     Abstract available


  64. TAKAHASHI T, Yamanaka T, Seto T, Harada H, et al
    Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30230.
    PubMed     Text format     Abstract available


  65. SLOTMAN BJ
    Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30193.
    PubMed     Text format    


    February 2017
  66. SCOTT JG, Berglund A, Schell MJ, Mihaylov I, et al
    A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
    Lancet Oncol. 2017;18:202-211.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: